Cargando…
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
Cancer immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized oncology. However, only a limited number of patients benefit from immunotherapy, and some cancers that initially respond to immunotherapy can ultimately relapse and progress. Thus, some studies have investigated co...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441058/ https://www.ncbi.nlm.nih.gov/pubmed/34137513 http://dx.doi.org/10.1002/cac2.12183 |